Lazard Asset Management
CHRS icon

Lazard Asset Management’s Coherus Oncology CHRS Stock Holding History

Lazard Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,514
Closed -$17.8K – 1978
2026
Q1 		$17.8K Buy
+10,514
New +$18.7K ﹤0.01% 1810
2024
Q4 		– Sell
-883,729
Closed -$919K – 2312
2024
Q3 		$919K Buy
883,729
+252,982
+40% +$347K ﹤0.01% 1108
2024
Q2 		$1.09M Buy
630,747
+243,047
+63% +$489K ﹤0.01% 959
2024
Q1 		$926K Buy
387,700
+374,307
+2,795% +$921K ﹤0.01% 937
2023
Q4 		$44K Sell
13,393
-443,192
-97% -$1.19M ﹤0.01% 1914
2023
Q3 		$1.71M Sell
456,585
-93,938
-17% -$434K ﹤0.01% 893
2023
Q2 		$2.35M Buy
550,523
+173,190
+46% +$1.02M ﹤0.01% 861
2023
Q1 		$2.58M Buy
377,333
+59,611
+19% +$463K ﹤0.01% 869
2022
Q4 		$2.52M Buy
317,722
+156,746
+97% +$1.21M ﹤0.01% 872
2022
Q3 		$1.55M Buy
160,976
+152,754
+1,858% +$1.55M ﹤0.01% 932
2022
Q2 		$59K Sell
8,222
-14,666
-64% -$128K ﹤0.01% 1736
2022
Q1 		$295K Sell
22,888
-23,486
-51% -$299K ﹤0.01% 1194
2021
Q4 		$740K Buy
46,374
+38,531
+491% +$674K ﹤0.01% 1047
2021
Q3 		$126K Sell
7,843
-14,374
-65% -$211K ﹤0.01% 1363
2021
Q2 		$307K Sell
22,217
-62,859
-74% -$890K ﹤0.01% 1152
2021
Q1 		$1.24M Buy
85,076
+25,179
+42% +$427K ﹤0.01% 870
2020
Q4 		$1.04M Buy
+59,897
New +$1.07M ﹤0.01% 887
2017
Q3 		– Sell
-49,100
Closed -$704K – 989
2017
Q2 		$704K Buy
+49,100
New +$944K ﹤0.01% 682

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Lazard Asset Management's CHRS Position: Q2 2026 in Review

Lazard Asset Management sold out of Coherus Oncology (CHRS) in Q2 2026, closing a stake of 10,514 shares — an estimated $17.8K sold.

Lazard Asset Management first reported a position in CHRS in Q2 2017 and held it in 18 quarters. The position peaked at $2.58M in Q1 2023. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Lazard Asset Management reported no remaining Coherus Oncology position as of Q2 2026 after selling out during the quarter.
  • Lazard Asset Management sold 10,514 Coherus Oncology shares in Q2 2026, an estimated $17.8K.
  • Lazard Asset Management first reported a position in Coherus Oncology in Q2 2017 and held it in 18 quarters.
  • Lazard Asset Management's Coherus Oncology position peaked at $2.58M in Q1 2023.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.